F10 and atrial fibrillation: The AUGUSTUS trial investigated the combination of the factor Xa-inhibitor apixaban (in the approved dose of 2*5 mg/day or 2*2.5 mg/day in case of dose reduction criteria as in ARISTOTLE [17]) with mostly clopidogrel following PCI and/or an acute coronary syndrome in AF.